PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1430629
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1430629
The Europe and Middle East heparin market is expected to reach USD 3,794,707.9 thousand by 2031 from USD 2,444,237.3 thousand in 2024, growing at a CAGR of 5.7% in the forecast period of 2024 to 2031.
Europe and Middle East Heparin Market, By Product Type (Low Molecular Weight Heparin (LMWH) and Unfractionated Heparin), Product (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, and Others), Mode of Administration (Subcutaneous, Intravenous, and Others), Packaging (10000 Unit, 25000 Unit, 5000 Unit, 1000 Unit, 100 Unit, 10 Unit, and Others), Source (Biological and Synthetic), Indication (Deep Vein Thrombosis, Pulmonary Embolism, Peripheral Artery Disease, Arterial thromboembolism, Myocardial Infarction, Atrial Fibrillation, and Others), Type (Generics and Branded), Container Type (Vials, Bags, Bottles, and Others), Packaging Material (Glass and Plastic), End User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy & Drug Store, Online Pharmacy, and Others), Country (Germany, France, U.K., Italy, Spain, Switzerland, Austria, Poland, Turkey, Belgium, Malta, Romania, Czech Republic, Ireland, Portugal, Norway, Greece, Bulgaria, Slovakia, Cyprus, Estonia, Latvia, Croatia, Bosnia & Herzegovina, Rest of Europe, Saudi Arabia) - Industry Trends and Forecast to 2031.
Overview Europe and Middle East Heparin Market Dynamics
Drivers
Increasing research and development activities
Restraint
Increasing government restriction
Opportunity
Growing healthcare expenditure